Apr 29, 2020
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Feb 24, 2020
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
Sep 28, 2019
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Aug 16, 2019
With Over USD 4 Billion in Capital Investment, the Synthetic Lethality-based Drugs Market is Poised to Witness a Rapid Growth, Claims Roots Analysis
Jul 24, 2019
UT Southwestern Researchers find evidence a cancer drug may be extended to many more patients
Jun 21, 2019
BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Jan 25, 2019
Global PARP Inhibitors in Oncology Research Report 2018: Background, Mechanism of Action, and Clinical Development of PARP Inhibitors
Oct 30, 2018
DelveInsight: Triple Negative Breast Cancer (TNBC) - The Market for TNBC in G8 Countries is Increasing at a CAGR of 18.9% for the Study Period 2016-2027
Oct 16, 2018
BioMarin Receives Milestone Payments from Pfizer for Talzenna® (Talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Sep 06, 2018
Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab For The I-SPY 2 Trial For Breast Cancer
Aug 09, 2018
Sierra Oncology Reports Second Quarter Results
Apr 16, 2018
Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals' EP-100 Is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer
Feb 27, 2018
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study
Jan 12, 2018
FDA approves first treatment for breast cancer with a certain inherited genetic mutation
Oct 31, 2017
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer
Oct 04, 2017
Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY
Oct 03, 2017
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer
Jul 23, 2017
STA Signs Supply Agreement with TESARO